CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $123.81M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
123.81MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
23.45%vs all stocks
Market Capitalization
123.81MUSDvs all stocks (USD)
Enterprise Value
-5.76MUSDvs all stocks (USD)
Forward P/E
-1.46xvs Biotechnology peers
Price to Book (MRQ)
0.9241xvs Biotechnology peers
Enterprise to EBITDA
0.0720xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-35.79%vs Biotechnology peers
Return on Equity (TTM)
-68.40%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 9, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-79.91MUSDvs all stocks (USD)
Net Income (TTM)
-77.22MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-77.13MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-49.23MUSDvs all stocks (USD)
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-93.61MUSDvs all stocks (USD)
Pre-tax Income
-89.61MUSDFY2025 · Dec 31, 2025Income Tax Expense
49.00KUSDFY2025 · Dec 31, 2025Net Income
-89.66MUSDFY2025 · Dec 31, 2025EBIT
-93.61MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-88.47MUSDFY2025 · Dec 31, 2025Research & Development
71.04MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
22.57MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.02MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.12USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.12USDFY2025 · Dec 31, 2025Basic Shares Outstanding
42.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
42.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-89.66MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-77.93MUSDFY2025 · Dec 31, 2025Free Cash Flow
-78.19MUSDDerived from operating cash flow minus capital expenditure. This filing charges 5.15M of depreciation against 264K of capital expenditure, and its own free-cash-flow line reads -81.9M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
62.06MUSDFY2025 · Dec 31, 2025Income Tax Paid
82.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-89.66MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.14MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.61MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-935.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.09MUSDFY2025 · Dec 31, 2025Capital Expenditures
-264.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-93.97MUSDFY2025 · Dec 31, 2025Sale of Investments
79.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-15.23MUSDFY2025 · Dec 31, 2025Other Financing Charges
-413.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
107.69MUSDFY2025 · Dec 31, 2025Shares Outstanding
69.17MSharesUpdated Jul 9, 2026Float Shares
37.03MSharesUpdated Jul 9, 2026Shares Short
3.75MSharesUpdated Jul 9, 2026Short Ratio
4.38daysvs all stocks
Short % of Shares Outstanding
7.65%vs all stocks
% Held by Insiders
0.23%vs all stocks
% Held by Institutions
90.16%vs all stocks
Total Cash (MRQ)
132.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.91USDUpdated Jul 9, 2026Total Debt (MRQ)
16.56MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1236xvs Biotechnology peers
Current Ratio (MRQ)
14.98xvs Biotechnology peers
Book Value per Share (MRQ)
1.94USDUpdated Jul 9, 2026Total Assets
173.91MUSDvs all stocks (USD)
Total Current Assets
150.96MUSDFY2025 · Dec 31, 2025Total Liabilities
26.46MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.94MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
13.82MUSDFY2025 · Dec 31, 2025Total Current Liabilities
12.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
60.51MUSDFY2025 · Dec 31, 2025Other Short-term Investments
87.94MUSDFY2025 · Dec 31, 2025Accounts Payable
822.00KUSDFY2025 · Dec 31, 2025Short-term Debt
3.19MUSDFY2025 · Dec 31, 2025Long-term Debt
13.82MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-361.12MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
147.44MUSDvs all stocks (USD)
52-Week Low
1.01USDUpdated Jul 9, 202652-Week High
7.80USDUpdated Jul 9, 202652-Week Change
23.45%vs all stocks
50-Day MA
1.60USDUpdated Jul 9, 2026200-Day MA
4.05USDUpdated Jul 9, 2026Avg 10-Day Volume
703.38KSharesUpdated Jul 9, 2026Avg 30-Day Volume
707.61KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-1.46USDUpdated Jul 9, 2026Other Income / Expense
-11.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.92Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 14.98Altman Z-Score: -0.92
Financial Health
Altman Z-Score -0.92: distress zoneCritical
Altman Z-Score: -0.92
Low earnings qualitySignificant
Earnings Quality Score: -0.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $123.81M, lower than 95% of all stocks globallySignificant
Market cap (USD): 123,812,894Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Hebei Sinopack Electronic Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wave Life Sciences Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Doximity Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated